

## **NCI Best Practices for Biospecimen Resources**

### **Cost Recovery Models (Industry Perspective)**

Martin L. Ferguson, Ph.D.  
2007-11-05



# Academic biorepository cost recovery from industry

OBBR Office of Biorepositories  
and Biospecimen Research

- **Perspective**

- Limited to models used by Ardais Corp.

(one of several “tissue brokering” for-profits established in early 2000s)

- **Models**

- Grants – no expectations
- Grants or contracts - expectations



- **Common model**
- **Tissues may never leave clinical site.**
  - Analysis done onsite
  - Funder has right of first review of data, for IP
  - Publications OK



## Contracts – expectations of tissue

**OBBR** Office of Biorepositories  
and Biospecimen Research

- **Impossible to engage in an exchange of tissues for \$ without addressing ethical issues – widely, continuously**
- **Outright procurement**
  - Samples distributed between clinical entity to ensure both received per case representation whenever possible, otherwise random
  - No IP
- **Cost recovery is OK**
  - But not for personnel in decision making roles
  - Be careful that costs are even handedly charged
- **“Profit” OK, too**
  - But it better not go back to any administrative entity related to the operation.
    - Serve the mission of the institution
    - Patient groups representing the disease

# Contracts – expectations of tissue (cont'd)

- **Advantages for clinical site**
  - Capital investments can support other projects
    - SOPs, training, equipment, IT
  - Access to broader specimen pool
    - 3-tiers of specimens:

